Navigation Links
Drug delivery strategy eliminates myotonia symptoms in mice with myotonic dystrophy
Date:2/22/2013

New Rochelle, NY, February 21, 2013By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease. New classes of drugs called antisense oligonucleotides are being designed to achieve this. Innovative work to develop a modified antisense drug that can be administered intravenously and achieve the desired therapeutic effect is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Nucleic Acid Therapeutics website.

Andrew Leger and coauthors from Genzyme, a Sanofi Company (Framingham, MA) added a peptide to an oligonucleotide strand designed to bind to and inactivate the mutated RNA region associated with myotonic dystrophy type 1 (DM1). The disease can affect function of the heart, central nervous system, and gastrointestinal tract, and a characteristic symptom is myotonia, in which muscles are slow to relax following contraction.

In the article "Systemic Delivery of Peptide-Linked Morpholino Oligonucleotide Neutralizes Mutant RNA Toxicity in a Mouse Model of Myotonic Dystrophy," the authors describe how the peptide is intended to enable systemic delivery of the drug, protecting it from being damaged or destroyed in the body before it can reach its target, the muscles. They report that intravenous introduction of the drug in a mouse model of DM1 led to good biodistribution of the drug, evidence that the problems previously caused by RNA toxicity were corrected, and complete elimination of myotonia in the treated mice.

"One of the greatest challenges to the therapeutic use of nucleic acids is effective and safe delivery," says Executive Editor Fintan Steele, PhD, SomaLogic, Inc., Boulder, CO. "The work of Leger and his colleagues demonstrates a potentially powerful way to meet that challenge for many diseases."


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
2. Delivery of gene-therapy for heart disease boosted 100-fold; now in 100-patient trial
3. Light-induced delivery of nitric oxide eradicates drug-resistant bacteria
4. Oligonucleotide Delivery: Biology, Engineering and Development Conference
5. Elegant delivery
6. Pilot Results Move GHX Closer to Delivery of Healthcare Industrys First Implantable Device Supply Chain Solution
7. University of Leicester takes delivery of unique eye imaging equipment
8. Body heat, fermentation drive new drug-delivery micropump
9. UC Davis researchers develop new drug delivery system for bladder cancer using nanoparticles
10. Aware Enables Automated Delivery of Radiation Dose Information Through Integration With Leading Radiology Reporting System
11. Nanotechnology drug delivery shows promise for treatment of pediatric cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug delivery strategy eliminates myotonia symptoms in mice with myotonic dystrophy
(Date:11/22/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the company ... Life Sciences Awards as "Most Outstanding in eClinical ... year of recognition and growth for MedNet, which has ... iMedNet ™ , MedNet,s flagship ...
(Date:11/17/2016)... , Nov. 17, 2016  AIC announces that it has just released a new ... that require high-performance scale-out plus high speed data transfer storage solutions. Photo ... ... ... Setting up a high performance computing ...
(Date:11/14/2016)... Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), ... in challenging operating environments, announced its results for the ... a conference call to discuss these results on November ... Key Recent Accomplishments ... acquire Vislink Communication Systems. The purchase is expected to ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... 1, 2016   SurePure, Inc. (OTCQB: SURP) ... the Company has concluded an agreement with Tamarack Biotics ... 90-day period to acquire units of the Company,s patented ... 3.7 million.  Concurrently with the option, ... which Tamarack will seek regulatory approvals in ...
(Date:11/30/2016)... CA (PRWEB) , ... November 30, 2016 , ... ... a new moving magnet Voice Coil Actuator with a flexure design that ensures ... long life with cost-effective pricing and is ideally suited where extreme precision is ...
(Date:11/30/2016)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... to announce the formation of EyGen, Ltd. a ... assets through proof of concept. EyGen,s lead asset ... Pharmaceuticals Limited and being developed for topical ophthalmic ... segment diseases. This agent has the potential to ...
(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ -  Equicare Health Inc ... has been recognized as one of the top 100 ... annual international listing that distinguishes the top digital health ... a great step forward this year continually upgrading our ... own customer base and team," says Len Grenier ...
Breaking Biology Technology: